VALIANTLAB

Valiant Laboratories Limited

· Pharma & Health
₹ CrorePeersALBERTDAVDHALEOSLABSZIMLABMEDICOMEDICAMEQANUHPHRAHCLWANBURY
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation2.02.16.0
+ Finance Costs0.10.21.8
+ Fair Value (Gains) / Losses0.00.9-1.1
+ Other Non-cash Items0.00.90.2
+ Other — Cash Effects are Investing / Financing0.00.0-0.0
+ Other Reconciling Items0.00.00.0
Changes in Working Capital
+ Inventories3.06.0-41.4
+ Trade Receivables — Current42.8-27.2-21.4
+ Other Financial Assets — Current-1.4-0.20.0
+ Other Financial Assets — Non-current0.00.01.2
+ Other Current Assets-12.9-18.0-16.2
+ Other Non-current Assets-8.620.60.4
+ Trade Payables — Current-21.414.853.3
+ Other Financial Liabilities — Current-1.0-0.01.1
+ Other Financial Liabilities — Non-current0.00.00.5
+ Other Current Liabilities-0.90.15.3
+ Provisions — Current0.00.00.1
+ Provisions — Non-current0.00.40.0
Cash from Operating Activities
Profit Before Tax (per I/S)-0.8-1.50.824.5
+ Total Adjustments (incl. Working Capital)1.70.4-10.2
Cash from Operations (pre-tax)0.9-1.2-9.4
+ Income Taxes Paid-1.0-2.51.0
Cash from Operating Activities1.91.3-10.4
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)45.9113.934.2
+ Disp of Fixed Assets0.00.10.0
+ Purchase of Investments (Equity / Debt)3.60.026.1
+ Payments on Futures / Forwards / Options / Swaps94.40.00.0
+ Receipts on Futures / Forwards / Options / Swaps0.023.40.0
+ Other Inflows / (Outflows) — Investing0.037.667.5
Cash from Investing Activities-143.9-52.87.3
Cash from Financing Activities
+ Proceeds from Issue of Shares135.90.010.9
+ Proceeds from Borrowings16.745.20.0
+ Repayment of Borrowings0.00.076.3
+ Interest Paid0.10.21.8
+ Other Inflows / (Outflows) — Financing0.0-0.369.0
Cash from Financing Activities152.444.71.8
Net Changes in Cash (pre-FX)10.5-6.8-1.4
Net Changes in Cash10.5-6.8-1.4
Closing Cash11.7
Reference Items
EBITDA-8.4-4.76.433.3
EBITDA Margin %-4.62-3.512.6910.87
Free Cash Flow (CFO − Capex)-44.0-112.5-44.6-44.6
Free Cash Flow to Equity-67.6-122.7
Free Cash Flow per Basic Share-8.10-20.72-8.22-8.22
Cash Flow to Net Income5.90-0.603.19
Cash Paid for Taxes-1.0-2.51.0
Cash Paid for Interest0.10.21.8
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.